NCT01115803 2019-02-05A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid TumorsEli Lilly and CompanyPhase 1 Terminated29 enrolled 19 charts
NCT00947167 2017-03-03A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine TumorsStanford UniversityPhase 2 Terminated4 enrolled 5 charts